LEXX and LEXXW Related Headlines
Go Back- Lexaria Bioscience CEO outlines 2025 progress and 2026 plans
- Lexaria Releases Annual Letter from the CEO
- Lexaria reports additional Phase 1b study results for drug delivery platform
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
- Lexaria achieves primary endpoint in Phase 1b GLP-1 study
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
- Lexaria extends pharmaceutical partnership agreement through April 2026
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
- Lexaria Bioscience hires advisory firm, receives 4 new patents
- Lexaria Bioscience Corp. Provides Strategic Update
- Lexaria Bioscience closes $4 million registered direct offering
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH
- Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
- Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
- Lexaria completes patient dosing in Phase 1b GLP-1 study
- Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
- GLP-1 "Arms Race" Broadens to Include Dozens of Companies
- Lexaria reports reduced side effects in GLP-1 drug trial
- Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
- Lexaria claims technology could reduce GLP-1 drug side effects
- Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
- Lexaria Bioscience (LEXX) Reaches Patent Milestone - 50 Patents Now Granted Worldwide
- Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
LEXX and LEXXW Related Press Releases
Go Back- Lexaria Releases Annual Letter from the CEO
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
- Lexaria Bioscience Corp. Provides Strategic Update
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
- Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
- Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
- GLP-1 "Arms Race" Broadens to Include Dozens of Companies
- Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
- Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
- Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
